Drug Profile
NN 9277
Alternative Names: GG-co-agonist 1177; NN9277; NNC 9204 1177Latest Information Update: 11 Aug 2020
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class Obesity therapies
- Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 30 Jun 2020 Discontinued - Phase-I for Obesity in USA (SC) due to prioritisation within the obesity care development portfolio
- 21 Jan 2020 NN 9277 is still in phase-I trials for Obesity (Novo Nordisk pipeline, January 2020)
- 03 Jan 2020 Novo Nordisk completes a phase I trial in Obesity in USA (NCT03308721) (SC)